PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF A HMG-COA REDUZASE ENZYME INHIBITOR AGENT AND A GASTROINTESTINAL LIPASE ENZYME INHIBITOR

摘要

The present invention refers to a pharmaceutical composition comprising a synergic combination of an enzyme HMG-CoA reductase inhibiting agent, such as active principle atorvastatin and a gastrointestinal lipase enzyme inhibiting agent, such as active principle orlistat, which are formulated in a single dosage unit to be administered orally, for treatment and control of diseases such as dyslipidemias (hypercholesterolemia and hypertriglyceridemia) and other related conditions.